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Angiogenic inhibitors delivered by the 
type III secretion system of tumor-targeting 
Salmonella typhimurium safely shrink tumors 
in mice
Lei Shi1,2, Bin Yu1,2,3, Chun‑Hui Cai4,5 and Jian‑Dong Huang1,2,6*
Abstract 
Despite of a growing number of bacterial species that apparently exhibit intrinsic tumor‑targeting properties, no 
bacterium is able to inhibit tumor growth completely in the immunocompetent hosts, due to its poor dissemination 
inside the tumors. Oxygen and inflammatory reaction form two barriers and restrain the spread of the bacteria inside 
the tumors. Here, we engineered a Salmonella typhimurium strain named ST8 which is safe and has limited ability to 
spread beyond the anaerobic regions of tumors. When injected systemically to tumor‑bearing immunocompetent 
mice, ST8 accumulated in tumors at levels at least 100‑fold greater than parental obligate anaerobic strain ST4. ST8/
pSEndo harboring therapeutic plasmids encoding Endostatin fused with a secreted protein SopA could target vascu‑
lature at the tumor periphery, can stably maintain and safely deliver a therapeutic vector, release angiogenic inhibitors 
through a type III secretion system (T3SS) to interfere with the pro‑angiogenic action of growth factors in tumors. 
Mice with murine CT26 colon cancer that had been injected with ST8/pSEndo showed efficient tumor suppression by 
inducing more severe necrosis and inhibiting blooding vessel density within tumors. Our findings provide a therapeu‑
tic platform for indirectly acting therapeutic strategies such as anti‑angiogenesis and immune therapy.
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Introduction
Previous studies of tumor have mostly focused on dis-
covering the genetic and epigenetic abnormality of 
cancer cells, which were used to explore therapeutic 
strategies against solid tumors (Kopnin 2000). During 
recent years, there has been intense interest in under-
standing the unique tumor microenvironment: hypoxia 
(Ke et  al. 2012), angiogenesis (Yamato et  al. 2012), het-
erogeneous cellular interaction (Leonardi et  al. 2012) 
and immunosuppressive environment (Shiao et al. 2011). 
These characteristics hamper the intratumoral delivery 
of therapeutic molecules and favor the development of 
treatment-resistant cells. Progresses in this field have 
enabled us to control the growth and metastasis of the 
solid tumor and develop new cancer treatment options.
Recently, more and more studies nicely show that some 
anaerobic bacteria can accumulate in tumor hypoxia 
regions after systemic infection and be used as tumor 
specific therapeutic agents in cancer therapy (Ber-
nardes et al. 2013; Hong et al. 2014; Moreno et al. 2010). 
Hypoxia resulted from irregular vascular network and 
immune suppression in the tumor microenvironment 
allowed these bacteria to replicate, accumulate and elicit 
locally restricted cytotoxic effects leading to a continu-
ous tumor regression. For instance, facultative anaerobic 
Salmonella contains lipolysaccharide and virulent factors 
which kill cancer cells directly and strongly trigger host 
immune system to destruct tumors (Fordham et al. 2012; 
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Lee 2012; Yoon et  al. 2011). Additionally, metabolically 
active bacteria can express a substantial amount of thera-
peutic molecules and continuously release them during 
infection. It leads to a high concentration of anti-cancer 
factors accumulated inside the solid tumors. These indi-
cated that engineered bacteria are well suited for incor-
porating multiple targets into a single system. A growing 
number of studies have reported the successful targeting 
and treatment of murine tumors by bacteria. Research-
ers found that the bacterial treatment to be effective only 
against relatively small tumors in immunocompromised 
nude mice; a complete regression of established tumors 
in immunocompetent hosts has been described rarely 
thus far (Friedlos et  al. 2008; Hu et  al. 2009; Nagakura 
et al. 2009).
No selected bacterium that is able to inhibit tumor 
growth completely, mainly by two reasons: (1) inflam-
matory reaction (mainly by neutrophils) and relatively 
high oxygen levels at the viable rim restrain the spread of 
obligate anaerobes; and (2) the outer layer of tumor tis-
sue was unaffected, in which the tumor cells rapidly pro-
liferate and invade surrounding tissues with the support 
of tumor vasculatures. Here, we confer Salmonella with 
limited ability to spread beyond the anaerobic regions of 
tumors to target blood vessels with bacterial expressed 
an angiogenic inhibitor, Endostatin, which are secreted 
through a type III secretion system (T3SS) to inter-
fere with the pro-angiogenic action of growth factors 
(O’Reilly et al. 1997). We used the engineered S. typhimu-
rium strain ST8 to deliver Endostatin fused with a type 
III secretion protein SopA in order to efficiently secrete 
by bacteria and diffuse through tumor tissue. The ability 
to diffuse through the tissues will augment therapeutic 
effects, and enable repression of blood vessels in the can-
cer cell proliferating regions.
Materials and methods
Bacterial strains and plasmid construction
Escherichia coli strain DH5α (Invitrogen) was used for 
cloning experiments. Salmonella typhimurium strain 
SL7207 stain has the following genotype: S. typhimurium 
2337-65 derivative hisG46, DEL407 [aroA::Tn10 (Tcs)] 
was obtained from Dr. B.A.D. Stocker (1981). Plasmid 
pSim6 was a gift from Dr. D.L. Court (2006). All bacterial 
strains used in this study are listed in Additional file  1: 
Table S1. Primers are listed in Additional file 1: Table S2. 
All S. typhimuriumn strains were grown in Luria broth 
(LB) containing 0.3  M sodium chloride to activate the 
expression of the T3SS.
Mammalian cell culture
Mouse colon cancer CT26 cell line was obtained from 
ATCC, and routinely cultured under conditions specified 
by the manufacturer. Human umbilical vein endothelial 
cells (HUVEC) were obtained from Dr. E.H.C. Tang from 
the Department of Pharmacology & Pharmacy, at the 
University of Hong Kong.
Western blot analysis
Condensed medium or homogenized tissues were col-
lected and lysed. The heat-denatured samples were 
loaded and separated by SDS-PAGE gel. When the elec-
trophoresis was ended, the protein samples in the gel 
were transferred onto PVDF membranes (Roche). Mem-
branes were blocked in 5  % non-fat milk in Tris-buffer 
saline with 0.1 % Tween-20, and further incubated with 
primary and secondary antibodies to detect the pres-
ence of different proteins and visualized by chemilumi-
nescence detection kit (Pierce). Antibodies against Flag 
(Sigma-Aldrich) and α-tubulin (Cell signaling technol-
ogy) were used. Corresponding horseradish peroxidase-
conjugated secondary antibodies were purchased from 
Invitrogen.
Bacterial distribution and plasmid stability test in vivo
After systemic administration, mice were killed and dif-
ferent organs were removed and weighted. Tissues were 
homogenized in 9 volumes of H2O and colony forming 
units (CFU) test of viable Salmonella were determined by 
plating serial dilutions on LB agar plates supplemented 
with streptomycin or the antibiotic corresponding to 
the construction plasmid as well as diaminopimelic acid 
(DAP) (Sigma-Aldrich).
Establishment of tumor xenografts and evaluation 
of therapeutic effects
BALB/c mice were obtained from the Laboratory Animal 
Unit of University of Hong Kong. 105 CT26 murine colon 
cancer cells were injected to the inguinal mammary fat 
pads of female mice (6–8 weeks of age). When the tumors 
reached ~400 mm3 in size, the mice were received treat-
ments. All animal procedures were approved by the Eth-
ics Committee of University of Hong Kong and done 
according to institutional guidelines.
Bacteria were injected through the tail vein 
(5 × 107 CFU/100 μl PBS). In control animals, PBS was 
injected in the same volume. Mice were examined and 
the tumor diameters were measured every other day in 
two dimensions with an external microcaliper. Subcuta-
neous tumor size was calculated by using the formula:
Histology and immunohistochemistry
Tumor samples and the normal organs from therapy 
studies were fixed immediately with 4  % paraformalde-
hyde. After incubation, the samples were washed and 
Tumor volume = length × width2 × 0.52.
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dehydrated in graded ethanol. After appropriate permea-
tion in xylene, the fixed tissues were embedded in paraf-
fin and followed by cutting 7 μm paraffin sections. Then 
they were de-paraffinised xylene twice and rehydrated in 
descending concentration of ethanol. Standard hematox-
ylin–eosin (H&E) staining of paraffin embedded tissue 
was used for histological examination.
The sections along the H&E stained slides were fur-
ther processed for immunohistochemisty. Heat-induced 
antigen retrieval was performed at temperature >95  °C 
in 10  mM sodium citrate buffer (pH6.0) and followed 
by cooling down at room temperature. Endogenous per-
oxidase activity was quenched by incubating with 3  % 
hydrogen peroxide for 10  min. Then the background 
staining was blocked by incubation with blocking buffer 
(0.1  % Triton X-100, 3  % BSA and 2  % normal donkey 
serum) for 1 h. These experiments were carried out using 
the following first antibodies: anti-Salmonella (Abcam), 
anti-Flag (Sigma-Aldrich), anti-CD105 (BD PharMingen) 
and anti-Ki67 (Sigma-Aldrich). After washing with PBS, 
horseradish peroxidase-conjugated secondary antibod-
ies were applied. Finally, the sections were stained with 
a freshly prepared 3,3′-diaminobenzidine (DAB) chro-
mogen using a DAB kit (DAKO) and then counterstained 
with hematoxylin. Photos were taken under Olympus 
BX51 microscope by using a bright-field illumination.
Determination of hemoglobin content in tumors
Tumors were weighted, homogenized in PBS buffer and 
centrifuged; the content of hemoglobin in the superna-
tant was analyzed by Drabkin’s reagent (Sigma-Aldrich) 
and normalized to the weighs.
Statistical analysis
All statistical analysis was performed with Prism soft-
ware (GraphPad Prism). Statistical comparisons between 
two groups were evaluated by student’s t test. All the data 
are represented as mean plus standard deviation (SD). 
The differences were considered statistically significant 
when P value was less than 0.05.
Results
Development and characterization of tumor‑targeting 
Salmonella strain ST8
Using enhanced recombineering methods, we previously 
developed an “obligate” anaerobic Salmonella strain 
YB1 and ST4 with enhanced host safety and anti-tumor 
activity (Guo et al. 2015; Shi et al. 2016; Yu et al. 2012). 
However, early metastases and viable tumor cells out-
side necrotic regions are well or partially oxygenated, 
which are inaccessible to obligate anaerobic bacteria. 
To increase the fitness in the non-hypoxic, outer rim of 
the solid tumor and metastases, replication-competent 
strains ST7 and ST8 have been developed (Fig.  1a; 
Additional file 1: Table S1). Strain ST8 is a derivative of 
S. typhimurium ST4 strain (Shi et  al. 2016), which has 
the following genotype: S. typhimurium 2337-65 deriva-
tive hisG46, △aroA::Tn10 (Tcs), △gmd::Plac-T7RNAP, 
△htrA::PpepT-asd-PsodA,△infA::Ptet-tetR. Chloram-
phenicol resistance gene in ST4 was eliminated by 
induction of Cre recombinase. Once the loxp sites have 
been removed, the transcription of asd gene is con-
trolled by the upstream htrA promoter, which resulted in 
a very leaky expression under normal oxygen levels. This 
mutant can penetrate into tumor tissue and effectively 
colonize viable regions of tumors otherwise unaffected 
by standard cancer therapy and express multiple thera-
peutic molecules.
Maintaining sustained levels of angiogenesis inhibitors 
is crucial for prolonged suppression of angiogenesis. The 
stability and copy number of therapeutic plasmid in bac-
terial hosts also significantly affect the expression level of 
target gene. To solve this problem, a small essential gene 
infA from E. coli (encoding for translation initiation fac-
tor 1, IF1) was inserted into the exogenous plasmid which 
has been deleted from the chromosome. As a conse-
quence, only plasmid-carrying bacterial cells can survive, 
making this strain totally dependent on the maintenance 
of the infA+ plasmid. We investigate wherever the exog-
enous plasmid pcDNA-infA (pcDNA derivative with 
E.coli infA locus) were stably present in vivo by compar-
ing the total bacterial number with the amount of plas-
mid-carrying cells in murine tissue. After 7and 21 days, 
ST8/pcDNA-infA isolated from the tumors and plated 
onto agar plates with or without antibiotic selection. No 
statistic difference of colony forming units (CFU) was 
detected in total and recombinant bacteria carrying plas-
mids (Fig. 1b), indicating that the presence of exogenous 
plasmids in the bacteria did not compromise the growth 
of the bacteria and the plasmids were stably maintained 
in the bacteria over 3 weeks. In comparison, 100 % paren-
tal strain SL7207 had lost the plasmids at day 7 (Fig. 1c).
In addition, the bacterial distribution tests of ST4, ST7 
or ST8 strain in animals within the implanted tumors 
were investigated. Three groups of immunocompetent 
BALB/c mice were inoculated with CT26 colon cancer 
cells and when tumor volumes reached 300–500  mm3, 
a single dose (5 × 107) of bacteria was injected intrave-
nously. Bacterial distribution tests in the immunocom-
petent mice have shown that systemically injected ST8 
and control strain ST7 (without hypoxic control cir-
cuit), a large number of bacteria accumulate within the 
solid tumors, achieving about 108–109  cfu/gram tissues 
at day 14. Because of a high degree of bacterial accu-
mulation within tumors, these high titers can enhance 
the therapeutic effects, as the high amount therapeutic 
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molecules generated and delivered by bacteria. In con-
trast, the numbers of obligate anaerobes ST4 in tumors 
were only 105  cfu/gram (Fig.  2a). For ST7 inoculated 
mice, 103–105 CFU/gram of bacteria were found in nor-
mal organs. The unspecific accumulation of ST7 in livers 
caused hepatic injury (Fig.  2b). In comparison, tuning 
Fig. 1 Generation of a tumor‑targeting Salmonella strain ST8 for delivery and expression of multiple therapeutic factors. a Schematic diagram of 
the creation process of strain ST8. b CFU tests of ST8/pcDNA‑infA inside tumors of nude mice following intravenous injection. Tumors were col‑
lected at 7 and 20 days after bacterial infection, homogenized in PBS and plated onto agar plates with or without ampicillin selection to determine 
the counts of recombinant and total bacteria, respectively. Values are expressed as mean ± SD, n = 5. c SL7207/pcDNA‑infA infected tumors were 
homogenized and analyzed for the total bacterial number and total bacteria with the plasmids. ND stands for CFU = 0. Shown is the mean CFU per 
gram tissues plus SD
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survival gene asd expression cassette, ST8 was totally 
cleared from all the organs except the heavily immune-
suppressed microenvironment of metastases and pri-
mary tumor by 3  weeks (Additional file  1: Figure S1). 
ST8 treated tumors exhibited huge necrotic regions 
and a small viable rim surrounding the severe necrosis. 
Figure  2c shows a high magnification of a H&E-stained 
paraffin section of the ST8 infected tumors. The viable 
parts (V) of the tumor were stained purple, whereas the 
necrotic areas (N) of the tumor appear white. A more 
detailed examination of the distribution of ST8 inside 
the tumors revealed that it could target the outer rim 
and predominantly, although not exclusively, resided in 
the hypoxic/necrotic regions of the tumors. Controlled 
growth of ST8 could prevent a risk for sepsis in the clini-
cal setting.
Endostatin‑expressing ST8/pSEndo inhibits angiogenesis 
in vitro
Salmonella typhimurium possesses a T3SS, a macromo-
lecular, needle-like apparatus necessary for infection by 
secreted proteins (Galan and Wolf-Watz 2006). In this 
report, we modified Salmonella to bear a plasmid vector 
allowing for stable expression of angiogenic inhibitors. 
To endow the targeted S. typhimurium strain for secret-
ing endostatin, we used the plasmid pSEndo, in which a 
mouse Endostatin cDNA was fused with a N-terminal 
FLAG epitope tag and a SopA N-terminal sequence (the 
first 95 residues of SopA) which directs protein secre-




Fig. 2 The conversion of obligate anaerobic strain ST4 to ST8 could 
target the viable regions inside solid tumor and prevent the bacterial 
killing of the mice. a Distribution and tumor colonization of ST4, ST7 
and ST8 in tumor‑bearing nude mice. Different organs were collected 
at 14 days after bacterial infection and analyzed for the presence of 
bacteria (ND stands for CFU = 0). Shown is the mean CFU per gram 
tissues plus SD. b Representative histopathologic and immunohisto‑
chemical staining of Salmonella on liver sections as indicated. Scale 
bar 100 μm. Necrotic region was marked by N. c Representative 
histopathologic and immunohistochemical detection of Salmonella 
identified macroscopic regions of the viable region (marked with V), 





Fig. 3 ST8/pSEndo secretes recombinant SopA_Endostatin to target 
cells through the type III secretion system. a Diagram of plasmid 
pSEndo used in this study. b Plasmid pSGFP and pSEndo were intro‑
duced into ST8. ST8/pSEndo cells were exposed to cultured CT26 
cells and the presence of fusion protein in supernatants examined 
as described above. c Endothelial cell tube formation assay showed 
interference of network assembly of HUVEC cells on Matrigel in ST8/
pSEndo conditioned medium (right) compared with ST8/pSGFP 
conditioned medium (left)
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stimulated upon contact with eukaryotic cells. Hence, we 
exposed the ST8/pSEndo cultured epithelial CT26 cells at 
a multiplicity of infection (MOI) of 200 for 6 h and recov-
ered culture supernatant. The level of the fusion protein 
was assessed by western blot analysis of condensed cul-
ture medium (Fig. 3b).
We next studied whether the endostatin fusion pro-
teins secreted by ST8/pSEndo has direct anti-angiogenic 
effect on human endothelial cells. Conditioned medium 
(CM) was harvested from CT26 cells’ culture medium 
after 6  h exposure with ST8/pSEndo or ST8/pSGFP 
(mock control). ST8/pSEndo conditioned medium signif-
icantly inhibited the ability of HUVEC to form tube-like 
structures in a matrigel angiogenesis assay, whereas ST8/
pSGFP conditioned medium had no such effect (Fig. 3c). 
These data suggested that ST8/pSEndo could release bio-
logically active angiogenic inhibitors into the medium 
and inhibit in  vitro angiogenesis, which encouraged us 
to determine whether tumor inhibition by ST8/pSEndo 
could be realized in animal models.
Delivery of endostatin using ST8/pSEndo inhibits tumor 
angiogenesis
To assess in vivo effects, mice bearing established subcu-
taneous flank CT26 tumors were intravenously injected 
with ST8/pSEndo or ST8/pSGFP. After 14 days, the mice 
were sacrificed, and then tumors were excised. In animals 
that received ST8/pSEndo, tumor-specific expression of 
endostatin fusion protein was confirmed by western blot 
analysis (Fig. 4a). To study the bacterial colonization and 
distribution of endostatin inside the tumors, immuno-
histochemistry assays on tumor sections were carried 
out. As shown in Fig.  4b, Salmonella ST8 secretion of 
angiogenic inhibitors formed a spatial diffusion pattern 
throughout tumor tissues and target both necrotic and 
proliferative tumor regions, indicating that ST8/pSEndo 
successfully presents intratumoral pools of angiogenic 
inhibitors that diffused into surrounding tissue after col-
onization of tumors.
The endothelium in primary tumors was analyzed by 
detection of activated endothelial cell marker endoglin 
(CD105), which vascular expression is limited to prolif-
erating cells. Relative level of CD105 transcripts in ST8/
pSEndo treated tumors were 68.9  % (P =  0.0002) lower 
than those in mice injected with vector control ST8/
pSGFP (Fig. 4c). Imaging of the blood vessels by immuno-
histology indicated that continuous release of endostain 
fusion proteins within tumors successfully suppressed 
angiogenesis in comparison to the control group treated 
with ST8/pSGFP (Fig.  4d). The vessel densities corre-
lated with the mean hemoglobin content, with the ST8/
pSEndo treated animals showing significantly less hemo-
globin in tumors as compared to controls (P =  0.0012) 
(Fig.  4e). Devascularization caused by bacterial-medi-
ated anti-angiogenic therapy increases tumor hypoxia, 
and that this hypoxia accelerated the growth of bacteria 
which further augments the effect of loss of vascular sup-
port on the tumors.
Potent antitumor activities in experimental colon 
carcinoma by Salmonella mediated expression 
of angiogenic inhibitor endostatin
Most engineered bacteria were found to effective only 
against relatively small tumors in studies (Chen et  al. 
2009; Hong et  al. 2014; Zhao et  al. 2012), we tested the 
therapeutic effects of ST8/pSEndo on large tumors (initial 
size of 400–500 mm3). To evaluate the antitumor potency, 
we treated the immunocompetent mice harboring synge-
neic tumors by intravenous injections of PBS, ST8/pSGFP 
or ST8/pSEndo. Animals in the control groups were uni-
formly killed by tumors within 2 weeks, whereas the ST8-
mediated expression of secretable version of angiogenic 
inhibitors slowed a robust anti-tumoral effect and some-
times shrunk the established tumors, with all animals 
were alive during the observed time after bacterial injec-
tion (Fig.  5a). In addition, immunohistochemical detec-
tion of proliferating marker Ki67 also showed that the 
proliferating cells were largely reduced in the ST8/pSEndo 
group compared with ST8/pSGFP (Fig. 5b). Thus, ST8 has 
a propensity to multiply preferentially in solid tumors and 
consequently retards tumor growth.
During the treatments, the animals in the bacterially 
treated groups showed a transient weight loss. However, 
the observed weight loss was totally reversible after sev-
eral days post injections (Additional file  1: Figure S2). 
ST8/pSEndo infection did not result in the spleen swell-
ing (Additional file  1: Figure S3). Gross morphological 
examination of lung, liver and spleen showed that there 
were no detectable abnormal nodules and apoptotic cell 
death in the selected organ (Fig.  5c). Collectively, these 
experiments showed that ST8/pSEndo are well toler-
ated at the dosage selected and require 2–3 weeks for full 
clearance. Taken together, treatment with ST8/pSEndo 
reduced the number of tumor-associated blood vessels, 
and tumor size at later disease stages, without detectable 
systemic toxicity.
Discussion
To circumvent the problem of targeting genetically unsta-
ble tumor cells, another potential direction is to target 
stable, proliferating endothelial cells in the tumor vascu-
lature to inhibit angiogenesis (Weis and Cheresh 2011). 
It has been widely recognized that angiogenesis is a criti-
cal process required by solid tumors to support their 
growth. Here, we engineered a Salmonella strain ST8 to 
selectively grow within tumors, where they cause lysis of 
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tumor cells and secrete the biologically active angiogenic 
inhibitors in situ at high regional concentration, thereby 
achieving maximal inhibiting effects while sparing sys-
tem cytotoxity.
Previous studies have shown that the localization of 
antitumor proteins within live bacterial strains may play a 
key role in the therapeutic effects (Bernardes et al. 2013; 
Chen et al. 2011). Therefore, to elicit maximal antitumor 
responses, bacterial-mediated secretion of therapeutic 
factors without the requirement of bacterial lysis have 
been investigated in this study. Furthermore, to maintain 
of high protein production capacity in  vivo, ST8 strain 
bearing high-copy number plasmids encoding endostatin 
gene fused with location signal were used. Therefore, just 
a single dose of administration is needed instead of daily 
administration of the proteins. As a result, the cost and 
time could be saved and the variation of therapeutic pro-





Fig. 4 Injection of ST8/pSEndo significantly retards tumor angiogenesis. Detection of Flag‑SEndo expression in the ST8/pSEndo treated tumors by 
western blot analysis (a) and immunohistochemical assay (b). b Composite images of a whole tumor infected with ST8/pSEndo stained to visualize 
bacteria (left) and Flag‑SEndo (right). Immunohistochemical assay on tumor sections revealed that the therapeutic polypeptide diffused around the 
bacteria and some molecules have been found to be transferred to the outer rim. Quantitative RT‑PCR analysis (c) and immunohistochemistry (d) 
to detect CD105‑positive endothelial cells in tissue sections from ST8/pSGFP or ST8/pSEndo treated tumors. Scale bar 100 μm. e Angiogenesis was 
analyzed by quantification of haemoglobin content (n = 3). *P < 0.05
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As has been proven by several laboratories, Salmo-
nella alone could induce modest antitumor effects in 
animal models although the mechanisms responsible 
for this are not yet fully understood (Hiroshima et  al. 
2013; Murakami et  al. 2015). The combination of bac-
teria with angiogenic inhibitors may elicit a strong 
synergistic effect and directly contribute to tumor 
destruction through the release of nitric oxide (Grif-
fon et  al. 1998), protease (Le Negrate et  al. 2008), 
pore-forming agents (Shi et  al. 2016) and therapeu-
tic factors. This dual mode of action through direct 
cell infection and extracellular secretion has not been 
described before and opens up new strategies for eradi-
cating cancer effectively through this kind of com-
bination. Lastly, it should be noted this therapeutic 
platform is not necessarily restricted to cancer. It is 
suitable for indirectly acting therapeutic strategies such 




Fig. 5 Therapeutic effects in the immunocompetent BALB/c mice with highly aggressive tumors elicited by ST8‑mediated secretion of Endostatin. 
a Potent treatment of large established tumors with ST8/pSEndo. CT26 murine tumor cells were implanted subcutaneously into BALB/c mice, and 
then the mice bearing large tumors received intravenous injections of the indicated strains. Values are expressed as mean ± SD (n = 5). **P < 0.01 
compared with vector control ST8/pSGFP. b Tumor proliferation was examined by Ki67 expression of primary tumors from ST8/pSGFP and ST8/
pSEndo treated mice. Scale bar 100 μm. c No apparent damages were found in any of the organs in the ST8/pSEndo treatment group. Scale bar 
100 μm
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